NEFSPARRI

Serial Number 97473305
606

Registration Progress

Application Filed
Jun 23, 2022
Under Examination
Jul 18, 2023
Approved for Publication
May 23, 2023
Published for Opposition
May 23, 2023
Registered

Trademark Image

NEFSPARRI

Basic Information

Serial Number
97473305
Filing Date
June 23, 2022
Published for Opposition
May 23, 2023
Abandonment Date
August 19, 2024
Drawing Code
4

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Aug 19, 2024
Classes
005

Rights Holder

Travere Therapeutics, Inc.

03
Address
Suite 300
3611 Valley Centre Drive
San Diego, CA 92130

Ownership History

Travere Therapeutics, Inc.

Original Applicant
03
San Diego, CA

Travere Therapeutics, Inc.

Owner at Publication
03
San Diego, CA

Legal Representation

Attorney
Jared M. Barrett

USPTO Deadlines

All Deadlines Cleared

All 2 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

14 events
Date Code Type Description Documents
Aug 19, 2024 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Loading...
Aug 19, 2024 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Dec 26, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Dec 22, 2023 EX1G S SOU EXTENSION 1 GRANTED Loading...
Dec 22, 2023 EXT1 S SOU EXTENSION 1 FILED Loading...
Dec 22, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jul 18, 2023 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
May 23, 2023 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
May 23, 2023 PUBO A PUBLISHED FOR OPPOSITION Loading...
May 3, 2023 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Apr 15, 2023 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Apr 4, 2023 DOCK D ASSIGNED TO EXAMINER Loading...
Jul 12, 2022 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jun 27, 2022 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
pharmaceutical preparations for the treatment of kidney disease; pharmaceutical preparations for the treatment of focal segmental glomerulosclerosis (FSGS); pharmaceutical preparations for the treatment of Immunoglobulin A Nephropathy (IgAN); pharmaceutical preparations for the treatment of Alport Syndrome; pharmaceutical preparations for the treatment of glomerulonephropathy; pharmaceutical preparations for the treatment of glomerulonephritis

Classification

International Classes
005